Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations

Abstract Background Gilteritinib is an established FLT3 inhibitor used to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring FLT3 mutations. Prior studies have predominantly evaluated gilteritinib as a posttransplant maintenance therapy in patients who undergo al...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yun-Tzu Lin, Xavier Cheng-Hong Tsai, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Jia-Hau Liu, Bor-Sheng Ko, Chieh-Lung Cheng, Sheng-Chieh Chou, Ming-En Lin, Chien-Chin Lin, Ming-Kai Chuang, Ming Yao, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer Nature 2026-06-01
Edice:	Blood Research
Témata:	Gilteritinib Post-HSCT maintenance FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitor Acute myeloid leukemia
On-line přístup:	https://doi.org/10.1007/s44313-026-00144-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!